LBY135, a novel anti‐DR5 agonistic antibody induces tumor cell–specific cytotoxic activity in human colon tumor cell lines and xenografts

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Drug Development Research

• Publication date

  2008-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ddr.20229
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• TRAIL signals to apoptosis in CLL cells primarily through TRAIL R-1 whereas cross-linked agonistic TRAIL R-2 antibodies facilitate signalling via TRAIL R-2

  2007cited by this paper
• TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL‐R1 whereas cross‐linked agonistic TRAIL‐R2 antibodies facilitate signalling via TRAIL‐R2

  2007cited by this paper
• Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity

  2006cited by this paper
• Herceptin: mechanisms of action and resistance.

  2006cited by this paper
• Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle.

  2004cited by this paper
• Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18

  2004influential reference
• Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy

  2004influential reference
• Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway.

  2004cited by this paper
• Inducible Silencing of KILLER/DR5 In vivo Promotes Bioluminescent Colon Tumor Xenograft Growth and Confers Resistance to Chemotherapeutic Agent 5-Fluorouracil

  2004cited by this paper
• Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

  2004cited by this paper
• Caspase-2 Can Function Upstream of Bid Cleavage in the TRAIL Apoptosis Pathway*

  2004cited by this paper
• A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera

  2003cited by this paper
• The TNF receptor superfamily

  2003cited by this paper
• A Novel High-Through-Put Assay for Screening of Pro-Apoptotic Drugs

  2002cited by this paper
• Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.

  2002influential reference
• Drug synergism: its detection and applications.

  2001cited by this paper
• Heterogeneity of Channel Catfish CTL with Respect to Target Recognition and Cytotoxic Mechanisms Employed1

  2001cited by this paper
• Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity

  2001cited by this paper
• Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.

  2001cited by this paper
• A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL.

  2000cited by this paper
• Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression.

  2000cited by this paper
• A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling.

  2000cited by this paper
• Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc

  2000cited by this paper
• [Mitochondria and apoptosis].

  2000cited by this paper
• Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

  1999cited by this paper
• Functional analysis of TRAIL receptors using monoclonal antibodies.

  1999cited by this paper
• To die or not to die—the quest of the TRAIL receptors

  1999cited by this paper
• Caspases

  1999cited by this paper
• Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.

  1999cited by this paper
• The IgG Fc receptor family

  1998influential reference
• Caspases: enemies within.

  1998cited by this paper
• Mitochondria and apoptosis.

  1998cited by this paper
• Death receptors: signaling and modulation.

  1998cited by this paper
• A novel receptor for Apo2L/TRAIL contains a truncated death domain.

  1997cited by this paper
• The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain.

  1997cited by this paper
• The Receptor for the Cytotoxic Ligand TRAIL

  1997cited by this paper
• Programmed cell death in animal development.

  1997cited by this paper
• TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL.

  1997cited by this paper
• Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

  1997cited by this paper
• Apoptosis by death factor.

  1997influential reference
• Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

  1997cited by this paper
• An antagonist decoy receptor and a death domain-containing receptor for TRAIL.

  1997influential reference
• Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*

  1996influential reference
• Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas.

  1995cited by this paper
• Identification and characterization of a new member of the TNF family that induces apoptosis.

  1995cited by this paper
• The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death.

  1994cited by this paper
• Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications.

  1993cited by this paper
• The Beige Mutation in the Mouse

  1979cited by this paper
• The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect.

  1979cited by this paper
• The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function.

  1979cited by this paper

• Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199

  2021cites this paper
• Design and synthesis of a luminescent iridium complex-peptide hybrid (IPH) that detects cancer cells and induces their apoptosis.

  2018cites this paper
• Luminescent Iridium Complex-Peptide Hybrids (IPHs) for Therapeutics of Cancer: Design and Synthesis of IPHs for Detection of Cancer Cells and Induction of Their Necrosis-Type Cell Death

  2018cites this paper
• TNF-related apoptosis-inducing ligand (TRAIL) as the potential therapeutic target in hematological malignancies.

  2018cites this paper
• University of Groningen Trail receptor-targeted therapy : strategies to enhance DR 4-and DR 5-induced apoptosis

  2017cites this paper
• Multivalent antibody-scTRAIL fusion proteins for tumor therapy : impact of format and targeting

  2017cites this paper
• TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo

  2016cites this paper
• Principles of antibody-mediated TNF receptor activation

  2015cites this paper
• TRAIL-based therapy in pediatric bone tumors: how to overcome resistance.

  2015cites this paper
• Imaging Caspase-3 Activation as a Marker of Apoptosis-Targeted Treatment Response in Cancer

  2015cites this paper
• Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function?

  2014cites this paper
• Trail receptor-targeted therapy : strategies to enhance DR4- and DR5-induced apoptosis

  2014cites this paper
• Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis

  2014cites this paper
• Trail receptor-targeted therapy : strategies to enhance DR4-and DR5-induced apoptosis

  2014cites this paper
• Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL

  2013cites this paper
• Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis

  2013cites this paper
• Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Induces Death Receptor 5 Networks That Are Highly Organized*

  2012cites this paper
• Ligand binding and receptor network formation in the tumor necrosis factor superfamily.

  2012cites this paper
• An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

  2011cites this paper
• Targeting apoptosis in cancer cells : improving TRAIL death receptor signaling

  2011cites this paper
• TRAIL receptor signaling and therapeutics

  2010cites this paper
• Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer.

  2010cites this paper